Patient-Reported Outcomes in the Era of Immunotherapy Trials.

J Thorac Oncol

Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan. Electronic address:

Published: April 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2021.02.014DOI Listing

Publication Analysis

Top Keywords

patient-reported outcomes
4
outcomes era
4
era immunotherapy
4
immunotherapy trials
4
patient-reported
1
era
1
immunotherapy
1
trials
1

Similar Publications

Objectives: We examined the health-related quality of life (HRQoL) during menopause transition (MT) among middle-aged Korean women.

Methods: This cross-sectional study comprised 2,290 middle-aged women who completed web-based questionnaires between 2020 and 2022. Based on self-reported menstrual cycle patterns, menopause status was classified as premenopausal, early or late transition, or postmenopausal.

View Article and Find Full Text PDF

Purpose: Although publicly available cancer-related information online and offline could help patients make informed decisions, it also poses challenges due to prevalent misinformation. Patients need proper provider guidance to ensure they use valid and relevant information in decisions. We identify effective communication approaches for providers when (1) discussing patient-identified information and (2) disagreeing with it.

View Article and Find Full Text PDF

Youth living with HIV (YLWH) face psychosocial challenges and HIV-related stigma, which impact adherence to antiretroviral therapy (ART). This study was designed to understand better the change in mental health symptoms and experiences with stigma among YLWH in Tanzania who completed the original pilot Sauti ya Vijana (SYV), a mental health and life skills group intervention. YLWH who completed SYV and demonstrated a change of ≥2 points in either direction on their Patient Health Questionnaire PHQ-9 (depression screener) from baseline to 18 months were purposively sampled.

View Article and Find Full Text PDF

Objectives: To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA).

Methods: The Strategies for glucocorticoid TApering in Rheumatoid arthritis (STAR) study was a double- blind, double-placebo randomised controlled trial including patients with RA receiving a stable dose of glucocorticoid 5 mg/day for ≥3 months and were in LDA for ≥3 months. Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before discontinuation or to taper prednisone by 1 mg/day every month until complete discontinuation, contingent on maintaining LDA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!